SOD
SOD (Superoxide Dismutase)
📚 관련 논문 (21편)
1. J Nutr Sci. 2025 Mar 14;14:e25. doi: 10.1017/jns.2025.13. eCollection 2025. Effects of green tea supplementation on antioxidant status and inflammatory markers in adults: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials. Dehzad MJ(1), Ghalanda
2. J Med Life. 2026 Jan;19(1):49-62. doi: 10.25122/jml-2025-0172. A proprietary herbal extract of ashwagandha root for stress and anxiety in healthy adults: a randomized, double-blind, three-arm, placebo-controlled efficacy and safety study. West RE(1), Biswas A(2), Rao R(3), Tayade H(4), Ademol
3. Int J Environ Res Public Health. 2019 May 9;16(9):1628. doi: 10.3390/ijerph16091628. Biomarker Effects in Carassius auratus Exposure to Ofloxacin, Sulfamethoxazole and Ibuprofen. Yang X(1), Xu X(2), Wei X(3), Wan J(4), Zhang Y(5). Author information: (1)College of Biological and Chemical Eng
4. Br J Nutr. 2018 Jan;119(2):228-237. doi: 10.1017/S0007114517002926. Involvement of NLRP3 inflammasome in the impacts of sodium and potassium on insulin resistance in normotensive Asians. Wan Z(1), Wen W(1), Ren K(1), Zhou D(1), Liu J(1), Wu Y(1), Zhou J(1), Mu J(1), Yuan Z(1). Author informa
5. Nutrients. 2017 Oct 12;9(10):1110. doi: 10.3390/nu9101110. Combination of β-glucan and Morus alba L. Leaf Extract Promotes Metabolic Benefits in Mice Fed a High-Fat Diet. Xu J(1), Wang X(2), Cao K(3), Dong Z(4), Feng Z(5), Liu J(6). Author information: (1)Center for Mitochondrial Biology and
6. Am J Chin Med. 1998;26(2):133-41. doi: 10.1142/S0192415X9800018X. A protein-bound polysaccharide synergistic with lipopolysaccharide induces nitric oxide release and antioxidant enzyme activities in mouse peritoneal macrophages. Pang ZJ(1), Zhou M, Chen Y, Wan J. Author information: (1)Resea
1. Nutrients. 2026 Apr 12;18(8):1215. doi: 10.3390/nu18081215. Effect of Beetroot Nitrate Supplementation on Nitric Oxide Pathways and Oxy-Inflammatory Biomarkers in Amateur Triathletes: A Randomized Cross-Over Pilot Study. Mrakic-Sposta S(1), Vezzoli A(1), Parenza M(2), Magno M(2), D'Angelo G(2), Nannipieri F(3), Battaglia S(3), Solfanelli L(3), Tacconi E(4), Dellanoce C(1), Montorsi M(1)(5), Pratali L(2). Author information: (1)Institute of Clinical Physiology, National Research Council (IFC-CNR), Piazza dell'Ospedale Maggiore, 3, 20162 Milan, Italy. (2)Institute of Clinical Physiology, National Research Council (IFC-CNR), Via Giuseppe Moruzzi 1, 56124 Pisa, Italy. (3)Medical Research, Abiogen Pharma, Via Antonio Meucci, 36, 56121 Pisa, Italy. (4)Private Practice, Via Matteo Degli Organi 1, 59100 Prato, Italy. (5)Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Via di Val Cannuta, 247, 00166 Roma, Italy. Background/Objectives: Nitric oxide (NO) is a key mediator of vascular, metabolic, and redox pathways, influencing exercise performance. Beetroot, a natural source of inorganic nitrate, increases NO bioavailability and may modulate oxidative stress and inflammation, though data in endurance athletes remain limited. The aim of this study was to assess the effects of a novel beetroot-based nitrate supplement (B-bNs) on NO metabolism, oxidative stress, and inflammation in non-professional triathletes. Methods: This was a randomized 2 × 2 cross-over pilot study with two 7-day periods (B-bNs vs. No treatment), separated by a 15-day washout (4 visits: Day 1, 7, 22 and 28). Samples were collected at baseline (T0), 2 h post-first dose (T1), and after 7 days (T2) for the supplementation period (B-bNs) and at T0 and T2 for the "no treatment" period. The following biomarkers from plasma and urine were evaluated: NO pathway (NO metabolites (NOx), nitrite (NO2), inducible nitric oxide synthase (iNOS), peroxynitrite, 3-nitrotyrosine (3-NT)), oxidative stress (reactive oxygen species (ROS) production, 8-isoprostane, superoxide dismutase (SOD) activity), and cytokines (IL-6, IL-10). A total of 10 male triathletes (mean age 48.1 ± 9.8 years and BMI 23.9 ± 2.2 kg/m2) participated in this study. Results: No adverse events were reported. After 7 days of supplementation (T2 vs. T0), significant increases in NOx in plasma and urine (about +155%), iNOS (+56%), peroxynitrite (+60%), 3-NT (+8.6%), ROS (+413%) and IL-6 (+73%) were recorded. These values resulted significantly higher compared to "no treatment" (all p = 0.002), with no significant differences for 3-NT, SOD, 8-isoprostane, IL-6, and IL-10. Conclusions: Beetroot-based nitrate supplementation may enhance the NO-related pathway in non-professional endurance athletes with nitric-peroxydation activation, occurring without evidence of lipid oxidative damage. Larger placebo-controlled trials with standardized diet/training and performance outcomes are needed to determine the functional significance of these preliminary findings. This study was registered in the ISRCTN registry (ISRCTN10885376). DOI: 10.3390/nu18081215 PMID: 42075028 [Indexed for MEDLINE]
2. Nutr Metab Cardiovasc Dis. 2026 Jun;36(6):104608. doi: 10.1016/j.numecd.2026.104608. Epub 2026 Feb 4. Effect of a Chilean diet supplemented with Gevuina avellana molina versus a low-fat diet on cardiometabolic, oxidative stress, and inflammatory biomarkers in Chilean adults with hypercholesterolemia: A randomized controlled trial. Ramos-Pardo S(1), Ramírez-Alarcón K(2), González-Contreras C(3), Valdebenito E(4), Sureda A(5), Martorell M(6). Author information: (1)Centro de Vida Saludable, Universidad de Concepción, Concepción, Chile. Electronic address: sramos2016@udec.cl. (2)Departamento de Nutrición y Dietética, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Grupo en Nutrición Comunitaria y Estrés Oxidativo, Universidad de las Islas Baleares, Palma, Spain. Electronic address: karramir@udec.cl. (3)Centro de Vida Saludable, Universidad de Concepción, Concepción, Chile; Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Talcahuano, Chile. Electronic address: carlosalexgonza@udec.cl. (4)Centro de Vida Saludable, Universidad de Concepción, Concepción, Chile. Electronic address: evaldebenit2019@udec.cl. (5)Grupo en Nutrición Comunitaria y Estrés Oxidativo, Universidad de las Islas Baleares, Palma, Spain; Fundación Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: antoni.sureda@uib.es. (6)Centro de Vida Saludable, Universidad de Concepción, Concepción, Chile; Departamento de Nutrición y Dietética, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile. Electronic address: mmartorell@udec.cl. BACKGROUND AND AIMS: Cardiovascular diseases are strongly associated with oxidative stress and inflammation. Lifestyle modifications and hazelnut consumption have shown potential benefits in managing hypercholesterolemia. The aim was to compare the effects of a diet supplemented with Gevuina avellana with those of a low-fat diet on plasma oxidative stress and inflammatory biomarkers in adults with hypercholesterolemia. METHODS AND RESULTS: A six-month randomized controlled trial was conducted in adults with hypercholesterolemia (total cholesterol >200 mg/dL). Participants were allocated by block randomization, stratified by sex, to either an experimental group following a Chilean diet supplemented with G. avellana (30 g/day) or a control group adhering to a low-fat diet (ClinicalTrials.gov: NCT07087704). Blood samples were collected at baseline and after the intervention to assess lipid profiles, total antioxidant capacity (TAC), activities of superoxide dismutase (SOD) and catalase (CAT), as well as malondialdehyde (MDA), oxidized LDL (ox-LDL), homocysteine, nitrotyrosine (%NTYR), folic acid, C-reactive protein (CRP), adiponectin and lactate dehydrogenase (LDH). The primary outcome was the change in oxidative stress and inflammatory biomarkers. Biochemical analyses and statistical evaluations were performed in a blinded manner, and data were analyzed using linear mixed-effects models. A total of 106 participants were recruited and randomized, of whom 81 completed the intervention (experimental, n = 47; control, n = 34). Both groups exhibited a significant increase in HDL-C (+11%) and folic acid (+64%), along with a 35% reduction in LDH. CRP decreased significantly in both groups (p = 0.037), declining from 9.32 ± 2.45 to 5.20 ± 1.63 mg/dL in the control group and from 5.01 ± 1.13 to 2.82 ± 0.69 mg/dL in the experimental group. CAT activity significantly increased in both groups after the intervention period (p = 0.015), rising from 9.01 ± 1.34 to 16.26 ± 2.72 nKat/L in the control group and from 9.26 ± 1.10 to 18.10 ± 2.20 nKat/L in the experimental group, whereas no changes were observed in SOD activity. Homocysteine levels decreased by 35% in the control group and by 25% in the experimental group. No significant differences between groups were observed for oxidative or inflammatory biomarkers. CONCLUSION: Both diets improved oxidative and inflammatory markers in adults with hypercholesterolemia, with no evidence of superiority of one dietary approach over the other, highlighting the potential of hazelnuts as a dietary complement for managing hypercholesterolemia. Copyright © 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.numecd.2026.104608 PMID: 41791910 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare no conflict of interest.
3. Free Radic Biol Med. 2026 Apr;247:528-539. doi: 10.1016/j.freeradbiomed.2026.02.032. Epub 2026 Feb 12. Weizmannia coagulans BC99 alleviates alcohol-induced oxidative stress and gut barrier dysfunction via modulation of butyrate metabolism: A randomized, double-blind, placebo-controlled trial. Wang Y(1), Guo J(1), Dong Y(2), Zhu J(2), Fang S(2), Wu Y(3), Gu S(4). Author information: (1)College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471000, China. (2)Wecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou, 215200, China. (3)College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471000, China; Henan University-Enterprise R&D Center for Scientific Evidence-Based and Industrialization Application of Probiotics, Luo-yang, 471023, China. Electronic address: wuying2000@126.com. (4)College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471000, China; Henan University-Enterprise R&D Center for Scientific Evidence-Based and Industrialization Application of Probiotics, Luo-yang, 471023, China; Henan Engineering Research Center of Food Microbiology, Luoyang, 471000, China. Electronic address: shaobingu@haust.edu.cn. This randomized, double-blind, placebo-controlled clinical trial investigated the effects of Weizmannia coagulans BC99 on alcohol-related physiological disturbances in adults with chronic alcohol consumers. Sixty participants were randomly assigned to receive either BC99 or placebo for 60 days. Compared with placebo, BC99 supplementation significantly increased the activities of alcohol dehydrogenase (ADH)1 and aldehyde dehydrogenase (ALDH)2, indicating enhanced ethanol metabolism. BC99 improved serum lipid profiles, reflected by a significant reduction in triglycerides (TG)3. BC99 markedly alleviated oxidative stress, as shown by increased serum superoxide dismutase (SOD)4 and glutathione (GSH)5 and decreased malondialdehyde (MDA)6 and P450 2E1 (CYP2E1)7 levels. Serum lipopolysaccharide (LPS)8 concentrations were significantly reduced, suggesting improved intestinal barrier integrity. Fecal short-chain fatty acids (SCFAs)9, particularly butyrate, increased substantially following BC99 intervention. Untargeted serum metabolomics identified 590 differentially regulated metabolites after BC99 supplementation. KEGG enrichment analysis revealed significant modulation of metabolic pathways, including butyrate metabolism, purine metabolism, and histidine metabolism. Metabolites involved in butyrate metabolism were negatively correlated with LPS and oxidative stress biomarkers, indicating a potential mechanistic link between enhanced SCFA metabolism and improved systemic oxidative and inflammatory status. Collectively, BC99 supplementation improved alcohol metabolism, reduced oxidative stress, and supported intestinal barrier function in chronic alcohol consumers. These findings suggest that modulation of butyrate-related metabolic pathways may contribute to the protective effects of BC99, supporting its potential as a therapeutic probiotic for alcohol-related health disturbances. Copyright © 2026. Published by Elsevier Inc. DOI: 10.1016/j.freeradbiomed.2026.02.032 PMID: 41690607 [Indexed for MEDLINE] Conflict of interest statement: Conflict of interest
4. Arch Microbiol. 2026 Jan 21;208(3):147. doi: 10.1007/s00203-025-04648-x. Management of IBD through improving intestinal barrier function by a novel Lactiplantibacillus plantarum C4 strain. Samir A(1), Abdeldaim A(2). Author information: (1)Biochemistry Department, October University for Modern Sciences and Arts, Faculty of pharmacy, Giza, 12451, Egypt. samiraboelnoor@gmail.com. (2)Biochemistry Department, October University for Modern Sciences and Arts, Faculty of pharmacy, Giza, 12451, Egypt. Inflammatory bowel disease (IBD) is a globally wide spread chronic disease with remittent attacks. It causes many stressful symptoms which decrease the quality of life of the patients remarkably. IBD requires long term treatment due to its chronic nature. Probiotics are promising treatment approach for IBD due to its improve of the composition of the gut microbiota which have a great role in the development of colitis, in addition to its safety on the long term use in comparison to traditional treatment options. A novel promising Lactiplantibacillus strain, with superior probiotic potential, is tested for the management of colitis. Colitis was induced in different mice groups using dextran sodium sulphate. One group is treated by a commercial probiotic preparation, another group was treated with sulfasalazine and the last group was treated by the novel Lactiplantibacillus strain. Inflammation was assessed by measuring pro-inflammatory markers such as IL-6, IL1-β and TNF-α. Oxidative stress was determined by measuring, Catalase and SOD activities in addition to malondialdehyde level. The effect of Lactiplantibacillus strain on the intestinal barrier function was examined by measuring the expression levels of tight junction proteins of claudin1, occludin and zonula occludens1 in mice colon and CaCo2 cell line. The novel Lactiplantibacillus strain significantly decreased the inflammatory markers level and oxidative stress. It also strengthens the intestinal barrier by increasing the expression of tight junction proteins in colon tissue and CaCo2 cell line. The effect of the novel Lactiplantibacillus strain was comparable to sulfasalazine and over performed commercial probiotic preparation. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00203-025-04648-x PMID: 41563463 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate: The study was approved by MSA-faculty of Pharmacy-IACUC (approval ref PB22/REC22/2024PhD). Competing interests: The authors declare no competing interests. Ethical guidelines for animal experiments statement: All animal experiments comply with Guide for the care and use of laboratory animals, 8th Edition 2011, by National Research Council (US). Clinical trial number: Not applicable.
5. Int J Mol Sci. 2025 Dec 15;26(24):12054. doi: 10.3390/ijms262412054. Synergistic Effects of High-Intensity Interval Training and Asparagus officinalis L. Root Extract Supplementation on Metabolic Regulation, Oxidative Stress, and Inflammation in Overweight and Obese Adults. Prasertsri P(1), Padkao T(1), Boonla O(1), Buddhisa S(1), Prakobkaew N(1), Sripinyowanich S(2), Phoemsapthawee J(3). Author information: (1)Faculty of Allied Health Sciences, Burapha University, Chonburi 20131, Thailand. (2)Department of Science and Bioinnovation, Faculty of Liberal Arts and Science, Kasetsart University, Nakhon Pathom 73140, Thailand. (3)Department of Sports Science, Faculty of Sports and Health Science, Kasetsart University, Nakhon Pathom 73140, Thailand. Excess adiposity is associated with increased oxidative stress and inflammation, which contribute to metabolic dysregulation. Both exercise training and bioactive plant-derived compounds have been explored as therapeutic strategies to mitigate these effects. Asparagus (Asparagus officinalis L.) root extract, rich in ecdysteroids such as 20-hydroxyecdysone (20E), exhibits potent antioxidant and anti-inflammatory activities. This randomized controlled trial investigated the combined effects of high-intensity interval training (HIIT) and asparagus root extract (ARE) supplementation on metabolic parameters, oxidative stress, inflammatory biomarkers, and white blood cell counts in overweight and obese adults. Seventy-two participants aged 18-30 years with a body mass index ≥ 23 kg/m2 were randomly assigned to one of four groups: control (CON), ARE supplementation only (ARE), HIIT only (HIIT), and combined intervention (COM). The HIIT protocol comprised a modified Tabata regimen of progressive bodyweight intervals at 80-90% and 40-50% of maximal perceived exertion, performed three times per week for 12 weeks. Participants in the ARE and COM groups received a daily oral dose of ARE providing 1.71 ± 0.24 mg/kg/day of 20E. Compared with the CON group, the HIIT group showed significant reductions in total cholesterol (TC), the TC/high-density lipoprotein cholesterol (HDLC) ratio, and blood glucose levels, alongside significant increases in HDLC and superoxide dismutase (SOD) activity (all p < 0.05). The COM group demonstrated significant decreases in protein carbonyls and interleukin-6 levels and in the TC/HDLC ratio (all p < 0.05) as well as a significant increase in SOD activity (p = 0.002). The ARE group, meanwhile, exhibited significant increases in both SOD activity (p < 0.001) and malondialdehyde levels (p = 0.017). These findings suggest that combining HIIT with ARE supplementation produces synergistic improvements in oxidative and inflammatory status, whereas HIIT alone primarily enhances metabolic regulation in overweight and obese individuals. DOI: 10.3390/ijms262412054 PMCID: PMC12733034 PMID: 41465480 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.
6. Sci Rep. 2025 Nov 28;15(1):45636. doi: 10.1038/s41598-025-30617-x. Natural antioxidant substances improve oxidative stress and alleviate ulcerative colitis: a meta-analysis of randomized controlled trials. Yuan S(1), Cai L(2), Su M(3). Author information: (1)Department of General Surgery, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, China. (2)Department of Outpatient Office, Ningbo Mingzhou Hospital, Ningbo, China. (3)Department of Medical Oncology, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, China. mansuper045@163.com. Oxidative stress is a key driver of mucosal damage in ulcerative colitis (UC). Antioxidant supplementation may restore redox balance, but its clinical efficacy remains controversial. To evaluate the effects of natural antioxidant substances supplementation on oxidation/antioxidant biomarkers and clinical outcomes in UC patients. The databases included PubMed, Embase, Web of Science, and Cochrane Library (up to July 2025) were searched, and RCTs comparing oral antioxidants with placebo in UC were included. The primary outcomes were changes in oxidative stress markers (MDA, SOD, TAC, GPX). The secondary outcomes included the short IBD questionnaire (SIBDQ) score and the simple clinical colitis activity index (SCCAI) score. 9 articles involving 624 patients were included in this study. Compared to placebo group, antioxidant substances supplementation could significantly reduce the level of MDA (P = 0.001, SMD=-1.09, 95% CI -1.75 to -0.43), increased the levels of SOD, TAC, GPX in patients with UC (P = 0.02, SMD = 0.57, 95% CI 0.10 to 1.04; P = 0.0004, SMD = 0.74, 95% CI 0.33 to 1.16; P = 0.004, SMD = 0.69, 95% CI 0.22 to 1.16). In addition, antioxidant substances supplementation remarkably decreased the SCCAI score of UC patients (P = 0.04, SMD=-0.62, 95% CI -1.21 to -0.04), thus improving the disease activity. However, there is no significant difference in the change of IBDQ score (P = 0.13, SMD = 0.55, 95% CI -0.17 to 1.28). Natural antioxidant substances supplementation effectively enhanced antioxidant capacity and ameliorated oxidation status, improved the disease activity of UC patients, but had no significant impact on their quality of life. This study will provide a basis for the selection of adjuvant therapy drugs for UC. © 2025. The Author(s). DOI: 10.1038/s41598-025-30617-x PMCID: PMC12753649 PMID: 41315853 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.
7. Neuropsychopharmacol Rep. 2025 Dec;45(4):e70076. doi: 10.1002/npr2.70076. Vitamin D3 Supplementation Modulates Inflammatory Protein CHI3L1/YKL-40 and Oxidative Stress Status in Multiple Sclerosis. Asadpour S(1), Mazdeh M(2), Karimi J(3), Khodadadi I(3), Shafiee G(4). Author information: (1)Department of Clinical Biochemistry, Medicine School, Hamadan University of Medical Sciences, Hamadan, Iran. (2)Department of Neurology, School of Medicine, Hearing Disorder Research Center, Avicenna Institute of Clinical Sciences, Sina (Farshchian) Educational and Medical Center, Hamadan University of Medical Sciences, Hamadan, Iran. (3)Department of Clinical Biochemistry, School of Medicine, Nutrition Health Research Center, Institute of Health Sciences and Technology, Hamadan University of Medical Sciences, Hamadan, Iran. (4)Department of Clinical Biochemistry, Medicine School, Nutrition Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. OBJECTIVE: Multiple sclerosis (MS) is characterized by chronic neuroinflammation and oxidative stress. Vitamin D is believed to exert immunomodulatory and antioxidant effects, yet its impact on specific inflammatory proteins such as CHI3L1 (YKL-40) in MS remains unclear. This study evaluated whether 8-week vitamin D3 supplementation affects serum CHI3L1 levels, oxidative stress markers, and antioxidant enzyme activities in patients with MS. METHODS: In this single-arm pre-post clinical trial, 35 patients with MS (aged 30-56 years) received oral vitamin D3 supplementation (50 000 IU/week) for 8 weeks. Serum 25(OH)D and CHI3L1 levels were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits. oxidative stress markers were measured pre- and post-intervention using commercial colorimetric kits. Statistical analysis was performed using paired t-tests or Wilcoxon signed-rank tests. RESULTS: Vitamin D3 supplementation significantly increased serum 25(OH)D levels (20.80 ± 8.6 to 39.11 ± 12.26 ng/mL; p < 0.001). CHI3L1 concentration decreased by 21.7% (33.28 ± 8.9 to 26.05 ± 9.1 ng/mL; p < 0.001). oxidative stress was reduced, evidenced by lower TOS (1.55 ± 0.50 to 0.59 ± 0.23 mmol H2O2 equiv./L; p < 0.001) and MDA (0.08 ± 0.03 to 0.05 ± 0.026 nmol/mL; p < 0.001). Antioxidant capacity improved, as demonstrated by elevated TAC (0.622 ± 0.138 to 0.797 ± 0.15 mmol Fe2+/L; p < 0.001) and increased activities of SOD (10.5%; p < 0.001), CAT (19.5%; p < 0.001), and GPx (35.6%; p < 0.05). Significant inverse correlations were observed between serum 25(OH)D and CHI3L1 (r = -0.999, p < 0.001), TOS (r = -0.456, p = 0.0058), and MDA (r = -0.577, p < 0.001). CONCLUSION: Vitamin D3 supplementation was associated with reductions in CHI3L1 and oxidative stress markers, while suggesting enhancement of antioxidant capacity. This observed biomarker changes support vitamin D3 as a potential adjunct therapy targeting interconnected pathological pathways in MS. © 2025 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology. DOI: 10.1002/npr2.70076 PMCID: PMC12641099 PMID: 41277171 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.
8. Front Immunol. 2025 Oct 24;16:1654724. doi: 10.3389/fimmu.2025.1654724. eCollection 2025. Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial. Li X(1)(2), Han Z(1), Wu K(3), Lin B(3), Azeem S(1), Jiang Y(1), Dong Y(4), Gai Z(4), Fang S(4), Wu Y(1)(5), Gu S(1)(2)(5). Author information: (1)College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China. (2)Henan Engineering Research Center of Food Microbiology, Luoyang, China. (3)Guangdong Yi Chao Biological Technology Co., Ltd., Shantou, China. (4)Department of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, China. (5)Henan Engineering Research Center of Food Material, Henan University of Science and Technology, Luoyang, China. BACKGROUND: Probiotics have demonstrated potential application value in alleviating allergic diseases, but their mechanisms of action remain to be explored. This study aimed to investigate the clinical efficacy of probiotics in patients with allergic rhinitis (AR) and explore the underlying mechanisms. METHODS: We evaluated the clinical intervention efficacy of Weizmannia coagulans BC99 (BC99) in adults with AR through a randomized, double-blind, placebo-controlled trial. Seventy-eight AR patients were randomly assigned to either the BC99 gummies group (n = 40) or the placebo group (n = 38) for an 8-week intervention. Rhinitis symptom survey questionnaires, including the Total Nasal Symptom Score (TNSS), the Rhinitis Quality of Life Questionnaire (RQLQ), and the Rhinitis Control Assessment Test (RCAT), were administered and evaluated. Additionally, oxidative stress indicators, including superoxide dismutase (SOD), glutathione (GSH), and malondialdehyde (MDA), as well as immune factors (IgA, complement C3) were measured by enzyme-linked immunosorbent assay. Serum metabolomic profiles were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). RESULTS: The results indicated that BC99 significantly alleviated nasal symptoms and improved quality of life, as evidenced by reduced TNSS and RQLQ scores (p < 0.05) and increased RCAT scores (p < 0.01). Furthermore, BC99 supplementation significantly decreased serum IgA, complement C3, EOS, and MDA levels (p < 0.05) while enhancing antioxidant capacity (increased GSH, stabilized SOD). Metabolomic analysis revealed that BC99 intervention induced 397 differential metabolite changes (136 upregulated, 261 downregulated) and significantly modulated AR-related metabolic pathways, including biosynthesis of unsaturated fatty acids, phenylalanine metabolism, and arginine biosynthesis (p < 0.05). CONCLUSION: This study confirms the efficacy of W. coagulans BC99 in ameliorating AR, potentially through immune modulation, oxidative stress reduction, and metabolic pathway regulation. These findings support BC99 as a promising adjunct therapy for AR, though further research is warranted to elucidate its molecular mechanisms and long-term effects. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov, identifier NCT06680102. Copyright © 2025 Li, Han, Wu, Lin, Azeem, Jiang, Dong, Gai, Fang, Wu and Gu. DOI: 10.3389/fimmu.2025.1654724 PMCID: PMC12592054 PMID: 41208993 [Indexed for MEDLINE] Conflict of interest statement: Authors KW and BL were employed by Guangdong Yi Chao Biological Technology Co., Ltd. Authors YD, ZG, and SF were employed by Wecare Probiotics Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
9. Sci Rep. 2025 Nov 4;15(1):38514. doi: 10.1038/s41598-025-19180-7. Encapsulated oil palm phenolics lower blood pressure and improve antioxidant status in healthy adults: a phase one trial. Fairus S(1), Tadj NBMI(2), Ibrahim NI(2), Zulfarina MS(2), Saad QM(2), Leow SS(3), Mohamed IN(4). Author information: (1)Malaysian Palm Oil Board (MPOB), 6, Persiaran Institusi, Bandar Baru Bangi, 43000, Kajang, Selangor, Malaysia. syfairus@mpob.gov.my. (2)Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar TunRazak, Cheras, 56000, Kuala Lumpur, Malaysia. (3)Malaysian Palm Oil Board (MPOB), 6, Persiaran Institusi, Bandar Baru Bangi, 43000, Kajang, Selangor, Malaysia. (4)Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar TunRazak, Cheras, 56000, Kuala Lumpur, Malaysia. isanaina@ppukm.ukm.edu.my. Oil Palm Phenolics (OPP), derived from by-products of oil palm fruit processing, contain bioactive polyphenols with nutraceutical benefits. While the optimal dose has been suggested for both liquid and spray-dried preparations, their efficacy in humans requires further investigation. This study assesses the effects of encapsulated OPP powder on cardiovascular and antioxidant (AOX) parameters in healthy individuals. A double-blind, placebo-controlled trial with 97 healthy volunteers randomized into four groups: placebo, 250 mg, 1000 mg, and 1500 mg/d spray-dried encapsulated OPP for 60 days. Primary outcomes included changes in lipid profiles, systolic (SBP) and diastolic blood pressure (DBP), and AOX markers including glutathione peroxidase (GSH-Px), glutathione reductase (GR), total superoxide dismutase (T-SOD), and total AOX capacity (T-AOC). 250 mg/d OPP significantly reduced SBP and DBP at day 60 compared to baseline (SBP: p = 0.017; DBP: p < 0.001). T-AOC improved significantly with the 1500 mg/d at day 30 (p = 0.038). Higher doses OPP (1000 and 1500 mg/d) preserved GSH-Px levels, while placebo and 250 mg/d OPP showed declines. Encapsulated OPP improved AOX status without affecting lipid profiles while improves BP at low doses. These findings support its development as a dietary supplement, warranting further investigation into optimized dosages and long-term effects. © 2025. The Author(s). DOI: 10.1038/s41598-025-19180-7 PMCID: PMC12586694 PMID: 41188255 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.
10. BMC Cardiovasc Disord. 2025 Oct 29;25(1):779. doi: 10.1186/s12872-025-05260-z. Impact of astaxanthin on oxidative markers, uric acid, and clinical symptoms in heart failure: a randomized clinical trial. Mohammadi SG(1), Shafie D(2), Feizi A(3), Bagherniya M(4), Ahmadi AR(5), Kafeshani M(6). Author information: (1)Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. (2)Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. (3)Epidemiology and Biostatistics Department, Health School, Isfahan University of Medical Sciences, Isfahan, Iran. (4)Department of Community Nutrition, Food Security Research Center, School of Nutrition and Food Science Isfahan University of Medical Sciences, Isfahan, Iran. (5)Department of Biomedical Sciences, Women Research Center, Alzahra University, Tehran, Iran. (6)Nutrition and Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, PO Box 81745-151, Isfahan, Iran. kafeshani_nut@yahoo.com. BACKGROUND AND AIMS: Chronic heart failure (HF) is often linked to increased oxidative stress and metabolic issues like high uric acid, which can worsen outcomes. Astaxanthin (ASX), a strong antioxidant, may help reduce these harmful effects. This study aimed to investigate the effects of ASX supplementation on oxidative stress markers as the primary outcome and clinical symptoms in patients with HF. METHODS: In this randomized, double-blind, placebo-controlled clinical trial, 80 patients with HF were enrolled and randomly assigned to receive either ASX (20 mg/day) or a placebo (20 mg/day of maltodextrin) for 8 weeks. Biomarkers including total antioxidant capacity (TAC), malondialdehyde (MDA), superoxide dismutase (SOD), serum UA, and clinical symptoms (dyspnea, fatigue, appetite) were assessed pre-and post-intervention. RESULTS: After eight weeks, compared to the placebo group, participants receiving ASX supplementation showed a significant increase in TAC (0.12 vs. -0.04 mmol/L, P = 0.002) and SOD levels (156.92 vs. 36.14 U/mL, P < 0.001). In contrast, the ASX group demonstrated significantly greater reductions in MDA (-2.19 vs. -0.68 nmol/L, P < 0.001) and serum UA levels (-1.82 vs. -0.63 mg/dl, P = 0.003) compared to placebo. Furthermore, among ASX treated patients, improvements in dyspnea and fatigue were statistically significant (P < 0.001), while the increase in appetite was only marginally significant (P = 0.071). CONCLUSION: These findings suggest that ASX supplementation may be effective in improving oxidative stress biomarkers and clinical status in patients with HF. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20200429047235N3. Registered on 26 March 2024, prior to the enrollment of the first participant. http://irct.behdasht.gov.ir/trial/75913 . © 2025. The Author(s). DOI: 10.1186/s12872-025-05260-z PMCID: PMC12574148 PMID: 41162864 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate: The study protocol was reviewed and approved by the Ethics Committee of Isfahan University of Medical Sciences (approval code: IR.MUI.MED.REC.1402.099, approved on 19 March 2024) and trial registration (IRCT20200429047235N3, registered on 26 March 2024) were both completed before the enrollment of the first participant. Written informed consent was obtained from all participants prior to their enrollment in the study, ensuring their voluntary participation and adherence to ethical standards in research. The study was conducted in accordance with the principles of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
11. Trials. 2025 Oct 23;26(1):430. doi: 10.1186/s13063-025-09166-1. Effect of mixodin supplementation on inflammatory and oxidative stress markers, clinical symptoms, mental health, and quality of life in patients with migraine: study protocol for a randomized clinical trial. Askari MA(1), Vajdi M(2), Khorvash F(3), Yegdaneh A(4). Author information: (1)Student Research Committee, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. (2)Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran. mv.vajdi@gmail.com. (3)Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. (4)Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. yekdaneh@pharm.mui.ac.ir. BACKGROUND: Migraine is a highly prevalent neurological disorder related to severe, unilateral headache and symptoms such as vomiting, nausea, and photophobia. Growing evidence implicates oxidative stress and inflammation as key contributors to migraine pathophysiology, exacerbating symptoms and related mental health conditions. Mixodin is a novel bioactive formulation derived from natural compounds, including curcumin, piperine, and gingerol, which are well-established for their anti-inflammatory and antioxidant properties. While each component has shown potential in alleviating migraine-related symptoms, the combined therapeutic efficacy remains unclear. This study investigates whether the combined natural compounds in mixodin provide synergistic benefits in migraine management by targeting multiple underlying mechanisms. This study aims to examine the effects of mixodin supplementation on clinical symptoms, mental health, quality of life (QOL), inflammatory, and oxidative stress factors in patients with migraine. METHODS: This study is a randomized, double-blind, placebo-controlled clinical trial involving 60 patients diagnosed with migraine by a neurologist according to the ICHD-3 criteria. Eligible participants, aged 20 to 60 years, will be randomly assigned to one of two groups. The intervention group (n = 30) will receive two mixodin capsules daily for 8 weeks, each containing 300 mg of curcumin, 7.5 mg of gingerol, and 3.75 mg of piperine. The control group (n = 30) will receive two placebo capsules daily for the same duration. The primary outcome will be the clinical symptoms of migraine, including the frequency, severity, and duration of migraine attacks reported by patients. Secondary outcomes will include serum levels of high-sensitivity C-reactive protein (hs-CRP), calcitonin gene-related peptide (CGRP), total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA), superoxide dismutase (SOD), nitric oxide (NO), and assessments of mental health status and QOL. DISCUSSION: This clinical trial aims to evaluate the effects of mixodin supplementation on inflammatory markers, oxidative stress, migraine-related symptoms, mental health, and QOL in patients with migraine. The results may suggestion insights into underlying mechanisms and support the development of evidence-based clinical guidelines that incorporate anti-inflammatory and antioxidant strategies to enhance therapeutic outcomes in migraine management. TRIAL REGISTRATION: Iranian Registry of Clinical Trials ( www.irct.ir ) (ID: IRCT20241009063312N1). Registration date: 2024-12-15. TRIAL STATUS: The protocol is Version 2.0, March 01, 2025. Recruitment began November 11, 2024, and is anticipated to be completed by June 22, 2025. © 2025. The Author(s). DOI: 10.1186/s13063-025-09166-1 PMCID: PMC12548111 PMID: 41131591 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate {24}: The study protocol is drafted in accordance with the SPIRIT checklist and is approved by the Medical Ethics Committee of IUMS, Isfahan, Iran (ID: IR.MUI.MED.REC.1403.231). The current trial is registered at the Iranian Registry of Clinical (ID: IRCT20241009063312N1). This trial will be conducted in accordance with the principles outlined in the Declaration of Helsinki. During the initial visit, each participant will be fully informed about the potential risks and benefits of the study. We will emphasize the confidentiality of their personal information, address any questions they may have, and assure them that general study finding will be shared with them upon completion. The final results will also be published for the benefit of the broader research community, without disclosing any names or personal identifiers. Written informed consent will be obtained from all participants prior to enrollment. Importantly, this intervention will not interfere with the routine treatment of patients with migraine. Consent for publication {32}: This paper does not contain any personal data. Competing interests {28}: The authors declare that they have no competing interests.
12. Inflammopharmacology. 2025 Dec;33(12):7197-7216. doi: 10.1007/s10787-025-01994-6. Epub 2025 Oct 22. Antioxidant and anti-inflammatory effects of ginger supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials. Rjabi S(1), Barbarz H(2), Makhtoomi M(3), Ahmadi MR(4), Najafi HZ(2), Talakesh S(5), Nouri M(6), Askarpour M(7). Author information: (1)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Shiraz University of Medical Sciences, Shiraz, Iran. (2)Orthodontic Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. (3)Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. (4)School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. (5)Department of Periodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. (6)Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. (7)Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. askarpourmoein1994@gmail.com. BACKGROUND: Disturbance of inflammatory/oxidative status of the body is an important player in chronic disease pathophysiology. Ginger (Zingiber officinale Roscoe, Zingiberaceae) supplementation has been vastly investigated in this regard. The present dose-response meta-analysis is aimed at summing up the findings of existing literature. METHODS: Online databases of PubMed, Scopus, Web of Science Core Collection, and Google Scholar were searched for eligible randomised controlled trials (RCTs) on ginger supplementation. Outcome variables included: C-reactive protein (CRP), tumour necrosis factor α (TNF-α), interleukin-6 (IL-6), total antioxidant capacity (TAC), malondialdehyde (MDA), and superoxide dismutase (SOD). Findings were reported as weighted mean differences (WMDs). Subgroup analysis was conducted. Linear and non-linear associations between dosage/duration of intervention and the observed effects were assessed. Protocol registered in PROSPERO (CRD420251011148(. RESULTS: Twenty-nine RCTs were included. Our findings show that ginger supplementation improves all inflammation/anti-oxidant biomarkers, as follows: CRP (WMD = -0.86 mg/L; 95% CI = - 1.10, - 0.62), TNF-α (WMD = - 1.90 pg/mL; 95% CI = - 2.61, - 1.18), IL-6 (WMD = - 1.15 pg/mL; 95% CI = - 1.90, - 0.41), TAC (WMD = 0.22 mmol/L; 95% CI = 0.06, 0.38), MDA (WMD = - 0.76 mcmol/L; 95% CI = - 1.19, - 0.33), and SOD (WMD = 48.12 u/L; 95% CI = 30.57, 65.58). CONCLUSION: The effect of ginger on IL-6 seems to associate with the dosage and duration of intervention in a non-linear fashion. Ginger supplementation may improve inflammatory and antioxidant biomarkers, particularly in individuals with underlying health conditions. Given the high heterogeneity among studies, findings should be interpreted cautiously. © 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG. DOI: 10.1007/s10787-025-01994-6 PMID: 41123858 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Conflict of interest: The authors declared no conflicts of interest. Ethical approval: Not applicable.
13. Int J Mol Sci. 2025 Sep 23;26(19):9286. doi: 10.3390/ijms26199286. Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Yaikwawong M(1), Kamdee K(1), Chuengsamarn S(2). Author information: (1)Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. (2)Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakhon Nayok 26120, Thailand. Liver steatosis, the hallmark component of metabolic dysfunction-associated steatotic liver disease (MASLD), is particularly common among individuals with type 2 diabetes mellitus (T2DM). Shared mechanisms such as insulin resistance, oxidative stress, and chronic inflammation contribute to the coexistence of these conditions and accelerate disease progression, emphasizing the need for effective therapeutic strategies. In this 12-month, randomized, double-blind, placebo-controlled trial, 227 obese individuals with T2DM were assigned to receive either 1500 mg of curcumin daily or placebo. Curcumin significantly reduced liver fat content, liver stiffness, and glycated hemoglobin (HbA1c) compared with placebo (all p < 0.001). Improvements were also noted in inflammatory mediators, including interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) (all p < 0.001), reflecting curcumin's anti-inflammatory effects. Antioxidant benefits were evident, as total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) increased, while malondialdehyde levels decreased (all p < 0.001). Systematic safety assessments, including liver and kidney function tests, revealed no clinically significant abnormalities. Mild gastrointestinal discomfort was the most common non-serious adverse event. Overall, these findings support curcumin as a safe and effective adjunctive therapy for improving liver steatosis in obese patients with T2DM. DOI: 10.3390/ijms26199286 PMCID: PMC12525202 PMID: 41096556 [Indexed for MEDLINE] Conflict of interest statement: The authors have no conflicts of interest to report. The study’s funders had no involvement in its design.
14. Sci Rep. 2025 Aug 13;15(1):29632. doi: 10.1038/s41598-025-14701-w. The impact of almond supplementation on oxidative stress biomarkers: a systematic review and meta-analysis of randomized control trials. Kolahi A(1), Movahed S(2), Tejareh F(3), Saeedy SAG(4), Gholizadeh M(5). Author information: (1)Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. (2)Department of Nutrition, Electronic Health and Statistics Surveillance Research Center, Science and Research Branch, Islamic Azad University, Tehran, Iran. (3)Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. (4)Department of Paraclinic, School of Medicine, Herat University, Herat, Afghanistan. (5)Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mgholizadeh@sbmu.ac.ir. Oxidative stress, an imbalance between reactive oxygen species and antioxidants, contributes to chronic diseases. Almonds, rich in vitamin E, polyphenols, and monounsaturated fats, exhibit antioxidant potential, though their overall effects on oxidative biomarkers are unclear. This systematic review and meta-analysis evaluate almond supplementation's impact on these biomarkers in adults. Following PRISMA guidelines, PubMed, Scopus, and Web of Science were searched up to January 2025. Randomised controlled trials (RCTs) and crossover trials assessing biomarkers of antioxidant and oxidation status (e.g., malondialdehyde [MDA], superoxide dismutase [SOD], glutathione peroxidase [GPx], 8-hydroxy-2'-deoxyguanosine [8-OHdG], uric acid [UA]) were included. Risk of bias was evaluated using the Cochrane Tool, and random-effects models calculated weighted mean differences (WMDs) with 95% confidence intervals (CIs). Eight studies (5 RCTs, 3 crossover trials; n = 424) were included. Almond doses of > 60 g/day significantly reduced MDA (WMD = -0.46, p = 0.002), 8-OHdG (WMD = -5.83, p < 0.001), and UA (WMD = -0.64, p = 0.009), while increasing SOD (WMD = 2.02, p = 0.008). No effect was found for GPx (p = 0.270). High heterogeneity (I² = 92-96%) indicated variability in study design, dosage, and population. Almond supplementation (> 60 g/day) significantly improves oxidation status by reducing MDA, 8-OHdG, and UA while enhancing SOD activity. These findings support almonds as a functional food for oxidation management. However, high heterogeneity underscores the need for standardized trials to confirm optimal dosage, duration, and conditions. Trial registration: Prospero-CRD42025646264. © 2025. The Author(s). DOI: 10.1038/s41598-025-14701-w PMCID: PMC12350649 PMID: 40804320 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.
15. Front Immunol. 2025 Jul 16;16:1547888. doi: 10.3389/fimmu.2025.1547888. eCollection 2025. The effect of co-administration of vitamin E and C supplements on plasma oxidative stress biomarkers and antioxidant capacity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with meta-regression. Moabedi M(1)(2), Milajerdi A(3). Author information: (1)Students' Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran. (2)Department of Community Nutrition, School of Nutrition and Food Science, Nutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. (3)Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. BACKGROUND: There is no conclusion on the effect of vitamins E and C on plasma biomarkers of oxidative stress and antioxidant status. We conducted this meta-analysis to gain a clearer view of this area. METHODS: We performed a systematic search in online databases using the relevant keyword combination. Randomized controlled trials that investigated the effect of vitamins E and C simultaneously, compared with control, on oxidative stress and antioxidant status biomarkers were included in the analyses. RESULTS: A total of 17 trials were included in the meta-analysis, building a total sample size of 965. The dosage of vitamin E and C supplements varied from 54 to 536 and 250 to 1000 mg/d, respectively, across included studies. We found significant results for MDA [WMD: -0.38, 95% CI: -0.48, -0.28 µg/L, P <0.001], LP [WMD: -1.01, 95% CI: -1.49, -0.54 µg/L, P <0.001], TAC [WMD: 0.09, 95% CI: 0.05, 0.13 mmol/L, P <0.001], and GPx [WMD: 1251.74, 95% CI: 258.92, 2244.56 U/L, P = 0.013], but not for SOD [WMD: 16.69, 95% CI: -29.40, 62.78 U/L, P = 0.278]. Regarding subgroup analysis, only studies on unhealthy participants showed a significant effect on MDA [WMD: -1.62, 95% CI: -2.08, -1.15 µg/L, P <0.001] and TAC [WMD: 0.08, 95% CI: 0.03, 0.14 mmol/L, P <0.001], unlike LP, where significance was only observed in healthy adults [WMD: -0.41, 95% CI: -0.45, -0.37 µg/L, P <0.001]. Moreover, only studies in which a placebo was administered, supplementation of vitamins showed significant effects on MDA [WMD: -0.47, 95% CI: -0.58, -0.35 µg/L, P <0.001], LP [WMD: -1.28, 95% CI: -1.85, -0.72 µg/L, P <0.001], and TAC [WMD: 0.10, 95% CI: 0.05, 0.15 mmol/L, P <0.001]. CONCLUSION: Our review and analyses revealed that a combination of vitamin C and E has a beneficial effect on oxidative stress biomarkers and antioxidant status. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024590197, identifier CRD42024590197. Copyright © 2025 Moabedi and Milajerdi. DOI: 10.3389/fimmu.2025.1547888 PMCID: PMC12307169 PMID: 40740780 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.